drugset / Trial / NCT01646645

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT01646645 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see how well transfusions of T-cells work in treating CMV. T-cells are a type of white blood cell that helps protect the body from infection. A transfusion is the process by which blood from one person is transferred to the blood of another. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.

Timeline

Start
2012-07-13
Primary completion
2019-12-11
Completion
2019-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CMV-pp65 CTLs Cell therapy 1e+06 cells/kg Intravenous